Ottawa, June 20, 2022: PDCI study finds Canada Ranks 10th on its Attractiveness for New Medicine Launch
Launched today by PDCI Market Access, a new study finds Canada ranks 10th out of 14 countries ... Read More
PDCI is excited to announce the launch of its new Webinar Series, kicking-off next month with the release of PDCI’s Biopharmaceutical Ecosystem Index: Where does Canada Rank on its Attractiveness for New Medicine Launch?During this calendar year, PDCI will host quarterly, lunchtime educational webinars, covering issues of interest to ... Read More
On May 3, 2022, CADTH announced the mandate expansion of the Scientific Advice Program to include advice on RWE generation plans after protocols for pivotal trials are finalized.
What to know:
The expanded program will run for a 1-year learning ... Read More
On April 14, 2022, Health Canada announced that the government will:
Proceed only with the proposed amendments to the Regulations pertaining to schedule of reference countries (the PMPRB11 replacing the PMPRB7). Not proceed with new excessive price factors (cost effectiveness, market size, GDP) nor the reporting of third-party ... Read More
The Canadian Agency for Drugs and Technologies in Health (CADTH) has published Issue 28 of its Pharmaceutical Reviews Update. Below PDCI has summarized the updates and clarifications, and provided implications for manufacturers. CADTH’s update also includes two consultations open until April 14, one concerning a streamlined drug class ... Read More
On March 31, 2022, PMPRB published its 2020 Annual Report on its website. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine investment and launch since drug pricing reform began in 2017.
Statistical Highlights201820192020Total # of Patented Medicines for Human Use Reported ... Read More
On September 29, 2021, the Attorney General of Canada applied for leave to appeal to the Supreme Court of Canada concerning the Federal Court of Appeal’s (FCA) July 2021 decision in Alexion Pharmaceuticals Inc v Canada (Attorney General). On March 24, 2022, the Supreme Court of Canada ... Read More
PDCI releases new issue of PDCI Market Access INSIGHTS, featuring research and opinion on the evolving state of private health insurance in Canada.
Volume 2, Issue 2
AnalyticsOur analytics article features ... Read More
On February 18, 2022, the Quebec Court of Appeal ruled that two of the three major proposed changes to the PMPRB price regulations are unconstitutional:
As more
information becomes available, PDCI will share further insights and
implications for ... Read More
This is a reminder to patentees of their filing requirements respecting revenues and development expenditures. These filing requirements are contained in section 5 of the Patented Medicines Regulations.
The Annual Form 3 filing to the PMPRB is due on March 1, 2022. As ... Read More
